Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Deszk – page 3

383 clinical trials in Deszk, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Deszk at a glance
383
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

383 trials in Deszk

Open in trial search

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Eltrekibart
  • Sponsor:Eli Lilly & Co.

Study on the Effects of Obicetrapib and Ezetimibe on Coronary Plaque in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ezetimibe
  • Sponsor:NewAmsterdam Pharma B.V.

Dermatomyositis+1

Recruiting

Study on Anifrolumab for Adults with Polymyositis or Dermatomyositis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study of Elafibranor for Adults with Primary Biliary Cholangitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Efficacy and safety of gadopiclenol versus gadoteric acid‑enhanced MRA in adult patients with suspected vascular disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Gadopiclenol
  • Sponsor:Bracco Imaging S.p.A.

Cardiac failure

Recruiting

Study on the Effects and Safety of Finerenone for Patients with Heart Failure Who Cannot Use Steroidal Mineralocorticoid Receptor Antagonists

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Efficacy and Safety of Intravitreal MK-8748 Compared with Aflibercept in Adults with Diabetic Macular Edema

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Merck Sharp & Dohme LLC

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Deszk

What the registry says about research in the country

01 Lung Cancer Research

Innovative clinical trials focusing on non-small cell lung cancer (NSCLC) treatments, particularly targeting advanced and unresectable cases.

  • Advanced Non-Squamous NSCLC with HER2 Mutations
  • Stage III Unresectable NSCLC
  • Combination Therapy Approaches

Studies evaluating novel therapeutic agents including zongertinib and combination treatments with durvalumab plus domvanalimab to improve patient outcomes.

02 Targeted Therapies

Research examining personalized treatment approaches for patients with specific genetic markers and protein expressions.

  • HER2 Mutation-Targeted Treatments
  • PD-L1 Expression Analysis
  • Immunotherapy Combinations

Investigations comparing new targeted therapies against standard-of-care treatments for better progression-free survival.

03 Treatment Innovation

Advancement in therapeutic strategies for locally advanced lung cancer patients.

  • Chemoradiation Therapy
  • Novel Drug Combinations
  • Biomarker-Driven Research

Focus on developing improved treatment options for patients with unresectable stage III NSCLC following concurrent chemoradiation.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.